Clinical trial · Observational
A Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
Retrospective Study to Determine Final Geriatric Assessment in Haematology (GAH) Score as a Tool for Predicting Tolerance to Treatment in Elderly Patients (≥ 65 Years) With Haematologic Neoplasms
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This is a post-authorization, retrospective multicentre observational nationwide study (PAS-OD). It will be conducted by reviewing medical records and database of patients who participated in the validation of the psychometric properties of the GAH study (CEL-GAH-2011-01). In all cases, only data prior to the start date of the study will be collected to ensure its retrospective nature, thereby reflecting routine clinical practice and non-interference in the physician's clinical practice
Conditions
Conditions (4)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia | ONTOLOGY_EXACT | 0.85 |
| Leukemia Myeloid Acute | Acute Myeloid Leukemia | ALIAS | 0.90 |
| Multiple Myeloma | Multiple Myeloma | CURATED_EXACT | 0.92 |
| Myelodysplastic Syndromes | Myelodysplastic Syndrome | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (1)
- label
- Patients with Haematologic Neoplasms
- description
- Patients with Myelodysplastic Syndromes (MDS), any IPSS (International Prognostic Scoring System) risk, or Acute Myeloid Leukemia (AML) who participated in the Geriatric Assessment in Haematology (GAH) study(CEL-GAH-2011-01). Patients with Multiple Myeloma (MM), symptomatic or asymptomatic who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01). Patients with Chronic Lymphocytic Leukemia who participated in the Geriatric Assessment in Haematology (GAH) study (CEL-GAH-2011-01).
Primary outcomes (8)
- measure
- Assessment of the tolerability of the treatment administered
- timeFrame
- Up to approximately 4 months
- description
- Number of patients, which suspend or modify treatment due to toxicity
- measure
- The score of number of drugs on the Geriatric Assessment in Haematology (GAH) scale
- timeFrame
- Up to approximately 4 months
- description
- Determination of number of drugs that patients were taken.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 65 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who were participating in the GAH study (CEL-GAH-2011-01). * Patients who have been scheduled to start treatment at a date less than three months after completion of the GAH (CEL-GAH-2011-01) scale in one of these visits: baseline, test-retest or sensitivity to change. * Patients who give informed consent to participate in the study as long as such consent is possible. Exclusion Criteria: • Not applicable
References
Publications (0)
Data not yet available